SEC Filing Summary: Harvard Bioscience, Inc. (HBIO)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on May 12, 2026. The filing serves to disclose a corporate slide presentation distributed to the investment community under Regulation FD (Item 7.01). The company is incorporated in Delaware and its common stock trades on the NASDAQ Capital Market under the symbol "HBIO."
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation rather than a financial statement containing audited or unaudited financial data.
Material Changes
No material changes to financial performance or operations are detailed within the text of this filing. The document solely references the distribution of a corporate presentation (Exhibit 99.1) to update the investment community.
Guidance, Outlook, and Risks
Management commentary, specific guidance, or detailed risk factors are not contained in the body of this filing. The content refers investors to the attached corporate slide presentation for business updates. The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Key Facts for Investor Verification
- Verify the contents of Exhibit 99.1 (Corporate slide presentation dated May 2026) for actual business updates and financial outlooks.
- Note that the presentation materials are not legally "filed" and do not carry the same liability protections as standard SEC filings.
- Confirm the company's status as a non-emerging growth company based on the unchecked box in the filing.
- Review the signature of Mark Frost, Chief Financial Officer, dated May 12, 2026.